Compare ABX & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABX | CMPX |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | 326 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.2M | 927.5M |
| IPO Year | N/A | 2020 |
| Metric | ABX | CMPX |
|---|---|---|
| Price | $8.35 | $5.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $11.00 | ★ $14.43 |
| AVG Volume (30 Days) | 666.6K | ★ 1.7M |
| Earning Date | 03-12-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.85 | N/A |
| Revenue Next Year | $6.54 | $677.91 |
| P/E Ratio | $74.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.18 | $1.33 |
| 52 Week High | $10.54 | $6.88 |
| Indicator | ABX | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 41.55 |
| Support Level | $7.18 | $4.86 |
| Resistance Level | $8.78 | $5.86 |
| Average True Range (ATR) | 0.48 | 0.29 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 1.59 | 36.26 |
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The company operates through four distinct yet complementary divisions: Abacus Life Solutions, Abacus Asset Group, Abacus Intel, and Abacus Wealth Advisors. It operates through three reportable segments, Asset management, Life solutions, and Technology services. It derives the majority revenue from Life solutions segment that generates revenues by buying, selling, and trading policies, and maintaining policies until receipt of death benefits. It also generates revenue by originating life insurance policy settlements between investors or buyers, and the sellers, who is often the original policy owner.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.